XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows Unaudited - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
CASH FLOWS USED IN OPERATING ACTIVITIES:    
Net loss for the period [1] $ (3,875) $ (1,828)
Adjustments to reconcile net loss to net cash from (used in) operating activities:    
Exchange differences on cash and cash equivalent 5 46
Finance expenses on lease liabilities (3)
Amortization of intangible assets 384 347
Depreciation 6 3
Loss from change in the fair value of a financial asset at fair value 57 90
Equity losses [1] 245 89
Change in fair value of derivative liabilities 730 (341)
Changes in deferred taxes, net (27) (27)
Issuance costs of financial instruments classified as derivative liabilities 603
Changes in operating assets and liabilities:    
Decrease in trade receivables 233 196
Increase in related parties balance (88) (2)
Decrease (increase) in operating lease right-of-use assets 42 (30)
Increase (decrease) in operating lease liabilities (42) 31
Decrease in other receivables 151 219
Increase in inventory (1,968) (752)
Increase (decrease) in accounts payable and other payables 13 790
Net cash used in operating activities (3,534) (1,169)
CASH FLOWS USED IN INVESTING ACTIVITIES:    
Purchase of property and equipment (8) (8)
Purchase of investment accounted for using the equity method (see note 3.a) (98) (2,993)
Purchase of intangible asset (see note 5) (330) (1,682)
Net cash used in investing activities (436) (4,683)
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:    
Short term loan repaid (86)
Issuance of ordinary shares, pre-funded warrants and warrants, net 6,255
Net cash from (used in) financing activities 6,255 (86)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 2,285 (5,938)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD 535 8,137
LOSSES FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS (5) (46)
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD 2,815 2,153
Supplemental disclosure of cash flow information:    
Taxes paid 92 28
Interest paid 2
Supplemental disclosure of noncash investing and financing activities:    
Issuance of ordinary shares to SciSparc Ltd. in consideration for ordinary shares (see note 3.b) 288
Consideration payable to sellers of Fort Products Ltd. included in other payables 349
Consideration payable to seller of SciSparc Nutraceuticals Inc. shares included in other payables $ 41
[1] Except share and per share information